Extracorporeal Membrane Oxygenation Cannula Market (2026 - 2033)

Extracorporeal Membrane Oxygenation Cannula Market Summary

The global extracorporeal membrane oxygenation cannula market size was valued at USD 35.0 million in 2025 and is projected to grow from USD 36.7 million in 2026 to USD 50.2 million in 2033, at a CAGR of 4.6% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of around 40.0% in 2025. The increasing prevalence of respiratory & cardiac disorders, rising geriatric population, and expanding applications of ECMO therapy are the major factors anticipated to propel market growth.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

In addition, the growing incidence of Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD), pneumonia, and heart failure, among others. For instance, in November 2024, the World Health Organization (WHO) reported that Chronic Obstructive Pulmonary Disease (COPD) caused approximately 3.4 million deaths in 2023, accounting for nearly 6% of all global deaths, while tobacco smoking accounts for more than 70% of COPD cases in high-income countries. The growing geriatric population has a significant impact on healthcare systems worldwide, particularly regarding the increased prevalence of age-related conditions such as heart and lung diseases.

Congestive heart failure, COPD, and pulmonary fibrosis often result in respiratory or cardiac failure, which may necessitate advanced life support measures, such as ECMO therapy. As a person ages, their organs may experience a decline in function, making them more susceptible to complications from existing conditions. In addition, age-related changes in the cardiovascular & pulmonary systems can increase the risk of severe respiratory or cardiac failure, necessitating interventions such as ECMO to support vital organ function during critical illness. ECMO is employed in cases of cardiac or respiratory failure where traditional management approaches, such as Cardiopulmonary Resuscitation (CPR), have proven ineffective.

The use of extracorporeal membrane oxygenation (ECMO) has improved across various medical applications, including Extracorporeal CO2 Removal (ECCO2R), pediatric & neonatal care, serving as a bridge to recovery or transplantation, in hospital transport, managing cardiac arrest, and addressing cardiac & respiratory failure. Moreover, the adoption of ECMO for in-hospital transport has increased in critical care settings. Furthermore, in September 2025, the National Center for Biotechnology Information (NCBI) published that ECMO continues to expand beyond conventional cardiac and respiratory failure management and is increasingly utilized for adults and children with life-threatening cardiopulmonary failure refractory to conventional therapies, including cardiogenic shock, severe ARDS, extracorporeal cardiopulmonary resuscitation (ECPR), and as a bridge to heart or lung transplantation. The continued expansion of ECMO indications and clinical practice is expected to support demand for ECMO cannulas during the forecast period.

Analyst Perspective

The industry is driven by the increasing investments in critical care infrastructure, the expansion of specialized ECMO centers, and the broadening of ECMO applications, such as respiratory support, extracorporeal cardiopulmonary resuscitation (ECPR), and bridge to transplant therapy. The developments in ECMO cannulas include enhanced biocompatibility, dual lumen cannulas, and less invasive cannulation techniques that increase the effectiveness and safety of procedures. Nevertheless, the market still faces issues associated with expensive ECMO procedures, a shortage of specialists, and the complex clinical aspects of their application, whereas innovations in the industry and access to healthcare are likely to drive the market.

Type Insights

The veno-arterial cannulae segment held the largest market share in 2025 and is expected to grow at the fastest CAGR from 2026 to 2033, driven by the widespread adoption of veno-arterial ECMO systems for providing both circulatory and respiratory support. In ECMO procedures, the return cannula is inserted into an artery while the drainage cannula is inserted into a vein to facilitate extracorporeal blood circulation. Veno-arterial ECMO is widely used in patients with severe cardiac and cardiopulmonary failure, supporting both heart and lung function during critical care interventions. The increasing preference for advanced circulatory support therapies in intensive care settings is expected to strengthen demand for veno-arterial ECMO cannulae.

The veno-venous (VV) cannula segment is anticipated to grow significantly during the forecast period due to its extensive use in managing severe respiratory disorders requiring extracorporeal respiratory support. This type of cannulation facilitates blood drainage and reinfusion through major veins, enabling effective oxygenation while preserving cardiac function. The increasing adoption of ECMO therapy in respiratory care is expected to drive demand for VV cannulae across healthcare facilities. In addition, advancements in dual-lumen and flexible cannula technologies are improving procedural efficiency and patient comfort, further driving segment expansion.

Patient Type Insights

The adult segment held the largest market share in 2025 and is expected to grow significantly over the forecast period due to the high incidence of severe respiratory and cardiac conditions that require ECMO support. The growing aging population and increasing number of critically ill adult patients continue to drive demand for ECMO cannulation procedures. The increasing use of ECMO therapy in intensive care units to manage complex cardiopulmonary conditions is expected to sustain market growth.

The pediatric segment is anticipated to register lucrative growth over the forecast period, owing to the increasing availability of ECMO cannulae specifically designed for neonatal and pediatric patients. Pediatric ECMO plays a crucial role in managing congenital cardiac disorders and severe respiratory complications in infants and children. Growing investments in pediatric critical care infrastructure are expected to support increased utilization of ECMO cannulation procedures.

Application Insights

The respiratory segment dominated the market in 2025 and is expected to grow significantly over the forecast period, driven by the extensive use of ECMO therapy to treat severe respiratory disorders requiring temporary pulmonary support. ECMO cannulae are essential components for maintaining efficient extracorporeal circulation and oxygenation during the management of respiratory failure. The increasing demand for advanced respiratory support systems in critical care settings is expected to drive growth in this segment. Furthermore, technological advancements that improve cannulation efficiency and reduce procedure-related complications are contributing to higher adoption rates.

The Extracorporeal Cardiopulmonary Resuscitation (ECPR) segment is anticipated to witness the fastest CAGR from 2026 to 2033, driven by the growing use of ECMO-assisted resuscitation for patients with refractory cardiac arrest. ECPR utilizes veno arterial ECMO cannulation to restore circulation and oxygen delivery when conventional resuscitation methods are insufficient. The increasing integration of ECMO into emergency and critical care protocols is expected to accelerate demand for specialized ECPR cannulae. In addition, continuous advancements in rapid cannulation techniques are improving procedural efficiency and expanding clinical applications.

End Use Insights

The hospitals segment held the largest market share in 2025, as hospitals remain the primary healthcare settings for performing ECMO procedures due to the availability of multidisciplinary critical care teams and advanced medical infrastructure. The increasing establishment of dedicated ECMO programs and specialized intensive care units continues to support the widespread adoption of ECMO cannulae. Rising investments in hospital-based critical care services are expected to further strengthen segment growth throughout the forecast period. Additionally, the availability of advanced imaging, surgical capabilities, and post-procedural monitoring enables hospitals to remain the leading end users of ECMO cannulation systems.

The ambulatory surgical centers (ASCs) segment is expected to register the fastest CAGR from 2026 to 2033, driven by the growing emphasis on expanding cardiovascular and minimally invasive surgical services in outpatient settings. Technological advancements and improvements in procedural efficiency are encouraging the adoption of ECMO-assisted interventions in select ambulatory care environments. The growing preference for cost-effective healthcare delivery models is expected to support the gradual adoption of ECMO cannulae in ASCs. Furthermore, ongoing investments in specialized surgical infrastructure are creating new opportunities for ECMO-assisted procedures in outpatient settings.

Regional Insights

The North America extracorporeal membrane oxygenation cannula market dominated with a revenue share of around 40.0% in 2025, owing to the established healthcare sector, commitment to innovation, advanced infrastructure, a strong emphasis on R&D, and high prevalence of chronic conditions, such as CVDs. As per the CDC, about 6 in 10 American adults suffer from at least one chronic condition that requires specialized care and attention. Moreover, favorable government regulations and reimbursement policies contribute to the region’s dominance. Regulatory bodies, such as the FDA, ensure rigorous quality standards, assuring healthcare professionals and patients of the safety & effectiveness of various healthcare products, including ECMO cannula.

To learn more about this report, Download Free Sample Report

U.S. Extracorporeal Membrane Oxygenation Cannula Market Trends

The extracorporeal membrane oxygenation cannula market in the U.S. accounted for about 33.0% of revenue in 2025. The prevalence of chronic diseases and the resulting rise in the number of cardiovascular surgeries in the U.S. are anticipated to propel the demand for ECMO cannulas. Approximately 150 million Americans suffer from at least one chronic illness, which frequently requires surgery, according to the CDC data. Respiratory problems and heart ailments are among the conditions that significantly contribute to the rising number of surgical procedures.

Europe Extracorporeal Membrane Oxygenation Cannula Market Trends

The extracorporeal membrane oxygenation cannula market in Europe is expected to witness significant growth due to rising adoption of ECMO therapies, favorable reimbursement policies, and increasing government investments in R&D for medical devices. However, the market landscape is competitive, with established players and emerging companies vying for market share.

The UK extracorporeal membrane oxygenation cannula market mirrors the European landscape, with dominant players such as Medtronic and Terumo. Emerging players such as LivaNova have a home advantage; all companies must navigate the NHS procurement process and prioritize cost-effectiveness. Collaborations with UK research and value-added services can be differentiators. Brexit adds some complexity, but the UK's focus on advanced therapies could drive demand for specialized cannulas.

The extracorporeal membrane oxygenation cannula market in France is expected to grow over the forecast period. Collaborations with local researchers and an understanding of French practices can give an advantage. This competitive market rewards companies that navigate AP HP procurement, prioritize affordability, and demonstrate value through local partnerships.

The Germany extracorporeal membrane oxygenation cannula market presents a distinct opportunity. Local market players such as Maquet Getinge experience a natural advantage, and established international companies remain formidable. While cost is a consideration, German hospitals prioritize solutions that deliver superior patient outcomes. Strategic partnerships with German research institutions and a deep understanding of these specific needs are considered crucial for success.

Asia Pacific Extracorporeal Membrane Oxygenation Cannula Market Trends

The extracorporeal membrane oxygenation cannula market in Asia Pacific presents a high growth opportunity, fueled by the rising adoption of ECMO therapy and government backing. However, the landscape is fragmented. Established players such as Medtronic hold strong positions, while regional competitors from China and India are emerging. Strategic partnerships with local players and the conduct of clinical trials in the region are considered essential for market growth.

The Japan extracorporeal membrane oxygenation cannula market prioritizes high-quality medical devices with proven safety and efficacy. Manufacturers need to showcase advanced cannula designs and materials. Navigating the strict regulatory requirements set by Japanese authorities, such as the Pharmaceuticals and Medical Devices Agency (PMDA), can cater to the specific needs of the market.

The extracorporeal membrane oxygenation cannula market in China is evolving, with a growing emphasis on domestic clinical trials and product approvals by the National Medical Products Administration (NMPA). There is a growing interest in innovative cannula designs and materials, with potential for domestic players to contribute to these advancements.

The India extracorporeal membrane oxygenation cannula market has a strong presence of established international players such as Medtronic and Terumo, and it faces competition from emerging domestic manufacturers aiming to capitalize on the growing demand and potentially offer cost-effective alternatives. Similar to China, affordability is a key consideration for hospitals in India. Companies need to be mindful of pricing strategies to cater to this price-sensitive market.

MEA Extracorporeal Membrane Oxygenation Cannula Market Trends

The extracorporeal membrane oxygenation cannula market in the MEA region is expected to experience moderate growth, driven by rising awareness of ECMO therapy and an increase in critical care facilities. Due to the specialized nature of ECMO cannulas, the number of major players in the MEA region is limited as compared to global markets.

The Saudi Arabia extracorporeal membrane oxygenation cannula market presents a unique opportunity in the Middle East. Saudi Arabia's Vision 2030 healthcare transformation plan is driving investments in advanced medical technologies, potentially boosting the ECMO cannula market.

The extracorporeal membrane oxygenation cannula market in Kuwait is restricted as the domestic production of ECMO cannulas is likely to be limited, making the market reliant on established international players such as Medtronic and Terumo. Kuwaiti hospitals might prioritize high quality, proven cannula designs from established brands due to the critical nature of ECMO therapies.

Key Extracorporeal Membrane Oxygenation Cannula Companies Insights

The ECMO cannula market is a dynamic and competitive space. Leading players such as Medtronic, LivaNova, and Getinge are constantly innovating and expanding their reach. These companies are aggressively pursuing organic and inorganic growth strategies. This includes developing new cannula technologies, forming strategic partnerships, and exploring acquisitions or mergers to solidify their market positions and address evolving customer needs.

Key Extracorporeal Membrane Oxygenation Cannula Companies

The following key companies have been profiled for this study on the extracorporeal membrane oxygenation cannula market:

• Medtronic

• LivaNova PLC

• Edwards Lifesciences Corporation

• Getinge

• Andocor

• Changzhou KangXin Medical Instruments Co., Ltd

• Free Life Medical GmbH

• Fresenius Medical Care AG

• Abbott

Recent Developments

• In July 2025, Medtronic announced CE Mark approval for the VitalFlow ECMO System. The approval strengthened Medtronic's extracorporeal life support portfolio, supporting broader adoption of integrated ECMO procedures that utilize compatible ECMO cannulation solutions for critical care applications.

• In January 2024, LivaNova PLC announced the wind-down of the Advanced Circulatory Support (ACS) business to focus on its Neuromodulation and Cardiopulmonary (CP) businesses. Livanova retains all ACS cannulae products through the CP business unit product portfolio.

Global Extracorporeal Membrane Oxygenation Cannula Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global extracorporeal membrane oxygenation cannula market report based on type, patient type, application, end-use, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Veno-Arterial

  • Veno-Venous

  • Arterio-Venous

• Patient Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Neonates

  • Pediatric

  • Adult

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Respiratory

  • Cardiac

  • ECPR

• End-use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals

  • Ambulatory Surgical Centers

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait